About 30 results found for searched term "Somatostatin Receptor" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3815 | Pasireotide | Somatostatin Receptor |
| SOM230 | ||
| Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. | ||
| M7372 | TC-G 1003 | Somatostatin Receptor |
| TCG1003 | ||
| TC-G 1003 is a high affinity somatostatin sst2 receptor agonist. | ||
| M25611 | Cyclosomatostatin acetate | Somatostatin Receptor |
| cycloSST | ||
| Cyclosomatostatin acetate is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin acetate can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells. | ||
| M10309 | CYN 154806 TFA | Peptides |
| CYN 154806 TFA is a cyclic octapeptide and an effective selective somatostatin sst2 receptor antagonist. | ||
| M11321 | Angiopeptin TFA | Somatostatin Receptor |
| Angiopeptin TFA, a cyclic octapeptide analog of somatostatin, is an SST2 / SST5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA inhibits growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential to be used in the study of coronary atherosclerosis. | ||
| M14062 | Octreotide | Somatostatin Receptor |
| SMS 201-995 | ||
| Octreotide is a somatostatin analog that binds to the somatostatin receptor, mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. | ||
| M14063 | Pasireotide acetate | Others |
| SOM230 acetate | ||
| Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). | ||
| M14064 | Pasireotide ditrifluoroacetate | Others |
| SOM230 ditrifluoroacetate; Pasireotide TFA salt | ||
| Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). | ||
| M14065 | Pasireotide L-aspartate salt | Others |
| SOM230 L-aspartate | ||
| Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). | ||
| M20861 | Somatostatin Acetate | Somatostatin Receptor |
| Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH(Cys3-Cys14) | ||
| Somatostatin Acetate is a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. | ||
| M28545 | BIM-23056 | Somatostatin Receptor |
| BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively. | ||
| M29328 | Paltusotine | Somatostatin Receptor |
| CRN00808 | ||
| Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy. | ||
| M29587 | J-2156 TFA | Somatostatin Receptor |
| J-2156 TFA is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats. | ||
| M29692 | Veldoreotide | Somatostatin Receptor |
| DG3173; PTR-3173 | ||
| Veldoreotide (DG3173) a somatostatin analogue, that can bind to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide. Veldoreotide has the potential to be used as pain modulating agent[1] | ||
| M30545 | Somatostatin-28 (sheep) | Somatostatin Receptor |
| Somatostatin-28 (sheep) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion. | ||
| M30684 | J-2156 | Somatostatin Receptor |
| J-2156 is a high potent, selective somatostatin receptor type 4 (SST4 receptor) agonist with IC50s of 0.05 nM and 0.07 nM for human and rat SST4 receptors, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats. | ||
| M31041 | BIM-23056 TFA | Somatostatin Receptor |
| BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively. | ||
| M41940 | PRL 3195 | Somatostatin Receptor |
| PRL 3195 is a somatostatin receptor antagonist with Kis of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst5, sst2, sst3, sst1 and sst4, respectively). | ||
| M41941 | DOTA-NOC | Somatostatin Receptor |
| DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. | ||
| M41942 | PRL 2915 | Somatostatin Receptor |
| PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst2) antagonist with a Ki of 12 nM. | ||
| M41944 | DOTA-LM3 TFA | Somatostatin Receptor |
| DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. | ||
| M41945 | DOTA-JR11 | Somatostatin Receptor |
| DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. | ||
| M41946 | DOTA-LM3 | Somatostatin Receptor |
| DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. | ||
| M52888 | Angiopeptin | Somatostatin Receptor |
| Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. | ||
| M52890 | Octreotide pamoate | Somatostatin Receptor |
| Octreotide (SMS 201-995) pamoate is a somatostatin receptor agonist and synthetic octapeptide endogenous somatostatin analogue. | ||
| M52893 | Cortistatin 14, human, rat | Somatostatin Receptor |
| Cortistatin 14, human, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor. | ||
| M52897 | BIM-23056 TFA | Somatostatin Receptor |
| BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively. | ||
| M53200 | Onzigolide | Dopamine Receptor |
| Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors. | ||
| M53256 | BIM 23042 | Bombesin Receptor |
| BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. | ||
| M53885 | Cortistatin-14 | Somatostatin Receptor |
| Cortistatin-14, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
